Evidence map›Paper›PMID 28195947›Full record

ArticleJournal of cardiovascular pharmacology2017

Alpha-Melanocyte-stimulating Hormone Induces Vasodilation and Exerts Cardioprotection Through the Heme-Oxygenase Pathway in Rat Hearts.

Miklos Vecsernyes, Miklos Szokol, Mariann Bombicz, Daniel Priksz, Rudolf Gesztelyi, Gabor Aron Fulop, Balazs Varga, Bela Juhasz, David Haines, Arpad Tosaki

Open access · hybridAbstract read
In one paragraph

Article in Journal of cardiovascular pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Synthesis, HScientific reports · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Miklos Vecsernyes*Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary; †Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; ‡Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary; §Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; and ¶Department of Cardiology, Faculty of Medicine, Division of Clinical Physiology, University of Debrecen, Debrecen, Hungary.
Miklos Szokol
Mariann Bombicz
Daniel Priksz
Rudolf Gesztelyi
Gabor Aron Fulop
Balazs Varga
Bela Juhasz
David Haines
Arpad Tosaki
University of Debrecen · HU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alpha-melanocyte-stimulating hormone (α-MSH) is a protein with known capacity for protection against cardiovascular ischemia-reperfusion (I/R) injury. This investigation evaluates the capacity of α-MSH to mitigate I/R effects in an isolated working rat heart model and determine the dependency of these alterations on the activity of heme oxygenase-1 (HO-1, hsp-32), a heat shock protein that functions as a major antioxidant defense molecule. Healthy male Sprague Dawley rats were used for all experiments. After treatment with selected doses of α-MSH, echocardiographic examinations were performed on live, anesthetized animals. Hearts were harvested from anesthetized rats pretreated with α-MSH and/or the HO-1 inhibitor SnPP, followed by cardiac function assessment on isolated working hearts, which were prepared using the Langendorff protocol. Induction of global ischemia was performed, followed by during reperfusion assessment of cardiac functions. Determination of incidence of cardiac arrhythmias was made by electrocardiogram. Major outcomes include echocardiographic data, suggesting that α-MSH has mild effects on systolic parameters, along with potent antiarrhythmic effects. Of particular significance was the specificity of dilatative effects on coronary vasculature, and similar outcomes of aortic ring experiments, which potentially allow different doses of the compound to be used to selectively target various portions of the vasculature for dilation.

Indexed as

alpha-MSHAnimalsAnti-Arrhythmia AgentsArrhythmias, CardiacCytoprotectionDisease Models, AnimalDose-Response Relationship, DrugEnzyme InhibitorsHeme Oxygenase (Decyclizing)Isolated Heart PreparationMaleMetalloporphyrinsMyocardial InfarctionMyocardial Reperfusion InjuryMyocardiumProtoporphyrinsalpha-MSHAnti-Arrhythmia AgentsEnzyme InhibitorsHeme Oxygenase (Decyclizing)Hmox1 protein, ratMetalloporphyrinsProtoporphyrinstin protoporphyrin IXVasodilator Agents

Identifiers

PMID28195947
PMCPMC5426697
OpenAlexW2588729311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.